Yueqin Zhao, PhD

Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

Poster(s):

• (067) Risk of Incident Inflammatory Bowel Disease in New Users of Dipeptidyl Peptidase 4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors in the FDA Sentinel System
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST